Knoll Capital Management LLC reduced its stake in Hookipa Pharma Inc (NASDAQ:HOOK – Free Report) by 90.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 551,738 shares of the company’s stock after selling 4,965,647 shares during the period. Hookipa Pharma comprises 1.2% of Knoll Capital Management LLC’s investment portfolio, making the stock its 18th largest position. Knoll Capital Management LLC owned 4.58% of Hookipa Pharma worth $2,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also bought and sold shares of the stock. Acadian Asset Management LLC increased its stake in shares of Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. Renaissance Technologies LLC increased its stake in shares of Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after buying an additional 83,800 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Hookipa Pharma during the first quarter valued at approximately $31,000. 63.88% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the company. Royal Bank of Canada reduced their price target on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. JMP Securities reduced their price target on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st.
Hookipa Pharma Trading Up 6.9 %
NASDAQ:HOOK opened at $2.48 on Friday. Hookipa Pharma Inc has a 12-month low of $2.08 and a 12-month high of $11.30. The stock has a 50-day moving average price of $3.65 and a 200 day moving average price of $5.36.
Hookipa Pharma Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Stories
- Five stocks we like better than Hookipa Pharma
- What is the Nikkei 225 index?
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Insider Trades May Not Tell You What You Think
- 3 Penny Stocks Ready to Break Out in 2025
- How to Find Undervalued Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.